{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:46:08Z","timestamp":1793079968137,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001396.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000}}],"reference-count":160,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001396.pub4","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T06:39:38Z","timestamp":1723617578000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder"],"prefix":"10.1002","volume":"2024","author":[{"given":"Cecilie","family":"Jespersen","sequence":"additional","affiliation":[{"name":"Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark; Department of Clinical Research, University of Southern Denmark; Odense Denmark"},{"name":"Open Patient data Explorative Network (OPEN); Odense University Hospital; Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Petri","family":"Lauritsen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology; Odense University Hospital; Odense Denmark"},{"name":"Faculty of Health Sciences; University of Copenhagen;  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibe G","family":"Frokjaer","sequence":"additional","affiliation":[{"name":"Neurobiology Research Unit, Department of Neurology; Rigshospitalet Copenhagen University Hospital; Copenhagen Denmark"},{"name":"Mental Health Services; Capital Region of Copenhagen; Brondby Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe B","family":"Schroll","sequence":"additional","affiliation":[{"name":"Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark; Department of Clinical Research, University of Southern Denmark; Odense Denmark"},{"name":"Open Patient data Explorative Network (OPEN); Odense University Hospital; Odense Denmark"},{"name":"Department of Gynecology and Obstetrics; Copenhagen University Hospital; Herlev Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"10.1002\/14651858.CD001396.pub4-BIB0001|cit1","first-page":"S28","article-title":"Relationship and response of food cravings and depression to sertraline in patients with premenstrual syndrome","volume":"October","author":"Arredondo-Soberon","year":"1997","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0924-977X(01)80189-9","article-title":"Efficacy of intermittent fluoxetine dosing in premenstrual dysphoric disorder (PMDD)","volume":"11","author":"Cohen","year":"2001","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub4-BIB0003|cit3","first-page":"435","article-title":"Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo controlled, clinical trial using computerized diaries","volume":"100","author":"Cohen","year":"2002","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0004|cit4","first-page":"204","article-title":"Intermittent fluoxetine dosing in premenstrual dysphoric syndrome","volume":"2 Suppl","author":"Judge","year":"2001","journal-title":"World Journal of Biological Psychiatry"},{"issue":"Suppl","key":"10.1002\/14651858.CD001396.pub4-BIB0005|cit5","first-page":"87","article-title":"Predictors of response to luteal phase fluoxetine treatment of PMDD","volume":"5","author":"Miner","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD001396.pub4-BIB0006|cit6","first-page":"111","article-title":"Paroxetine controlled release is effective in treating premenstrual dysphoric disorder","volume":"101","author":"Cohen","year":"2003","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.psy.0000140005.94790.9c","article-title":"Paroxetine controlled release for premenstrual dysphoric disorder: a double blind, placebo controlled trial","volume":"66","author":"Cohen","year":"2004","journal-title":"Psychosomatic Medicine"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0008|cit8","unstructured":"GlaxoSmithKline NZ Phone call from a representative of GlaxoSmithKline New Zealand (in response to an email sent by J Marjoribanks) confirming that 29060\/677 (Cohen 2004) and 29060\/689 (Pearlstein 2005) were separate studies"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0009|cit9","unstructured":"A double-blind, placebo-controlled, three-arm fixed-dose study of paroxetine CR continuous treatment (12.5 mg\/day and 25 mg\/day) for premenstrual dysphoric disorder www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F677&studyId=3742A8A5-2C3C-4A40-B9B5-7975DF70CF53&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0010|cit10","unstructured":"Email to Jane Marjoribanks from Teri Pearlstein advising that participants in Pearlstein 2005 and Cohen 2004 did not, to her knowledge, overlap."},{"key":"10.1002\/14651858.CD001396.pub4-BIB0011|cit11","unstructured":"Crnobaric C Jasovic-Gasic M Milanovanic S Miljevic C Treatment of premenstrual dysphoric disorder with fluoxetine during the luteal phase 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen (Denmark)"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0893-133X(94)00076-C","article-title":"The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome","volume":"12","author":"Eriksson","year":"1995","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/JCP.0b013e3181678a28","article-title":"Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder","volume":"28","author":"Eriksson","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/archpsyc.56.10.932","article-title":"Differential response to antidepressants in women with premenstrual syndrome","volume":"56","author":"Freeman","year":"1999","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1176\/appi.ajp.161.2.343","article-title":"Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder","volume":"161","author":"Freeman","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/archgenpsychiatry.2008.547","article-title":"Time to relapse after short-term or long-term sertraline treatment for severe premenstrual syndromes","volume":"66","author":"Freeman","year":"2009","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0017|cit17","unstructured":"Escitalopram for premenstrual syndrome (PMS) in teens: a pilot study clinicaltrials.gov\/ct2\/show\/NCT00523705"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0018|cit18","unstructured":"A multicentre, double-blind, placebo-controlled study to investigate the effects of paroxetine (5mg OD vs 10mg OD vs 20mg OD) in patients with premenstrual dysphoric disorder (PMDD) https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=29060\/427"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0019|cit19","unstructured":"A double-blind, placebo controlled study to investigate the efficacy, safety and tolerability of paroxetine in patients with premenstrual dysphoric disorder https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=29060\/400"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0020|cit20","unstructured":"A double-blind, placebo-controlled, 3-arm, fixed-dose study of paroxetine CR continuous treatment (12.5 mg\/day and 25 mg\/day) for premenstrual dysphoric disorder https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=29060\/688"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4088\/JCP.v58n0905","article-title":"Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome","volume":"58","author":"Halbreich","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001396.pub4-BIB0022|cit22","first-page":"248","article-title":"Intermittent (luteal phase) dosing of sertraline effective in PMDD","volume":"3","author":"Halbreich","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0023|cit23","unstructured":"Halbreich U Bergeron R Stout A Freeman E Yonkers K Pearlstein T Dosing of sertraline is effective in premenstrual dysphoric disorder 155th Annual Meeting of the American Psychiatric Association; 2000 May 18-23; Philadelphia (PA)"},{"issue":"6","key":"10.1002\/14651858.CD001396.pub4-BIB0024|cit24","first-page":"1219","article-title":"Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder","volume":"100","author":"Halbreich","year":"2002","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jad.2004.10.004","article-title":"Pretreatment pattern of symptom expression in premenstrual dysphoric disorder","volume":"85","author":"Pearlstein","year":"2005","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/archfami.8.4.328","article-title":"Luteal phase sertraline for the treatment of premenstrual dysphoric disorder","volume":"8","author":"Jermain","year":"1999","journal-title":"Archives of Family Medicine"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0027|cit27","unstructured":"Kornstein S Gillespie J Double blind placebo controlled study of sertraline in premenstrual syndrome 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA)"},{"issue":"10","key":"10.1002\/14651858.CD001396.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4088\/JCP.v67n1020","article-title":"Low dose sertraline in the treatment of moderate to severe premenstrual syndrome: efficacy of 3 dosing strategies","volume":"67","author":"Kornstein","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0029|cit29","unstructured":"Bellew KM Landen M Hunter B McCafferty JP Social functioning improves with paroxetine treatment 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA)"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0030|cit30","unstructured":"A placebo-controlled study to investigate the efficacy of intermittent and continuous treatment with paroxetine in patients with premenstrual dysphoric disorder (PMDD) www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F658&studyId=186F6412-CDE1-4505-8ACD-FBB1858393EB&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.npp.1301216","article-title":"Placebo controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder","volume":"32","author":"Landen","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0032|cit32","unstructured":"Landen M Sorvik K Ysander C Allgulander C Nissbrandt H Gezelius B A placebo controlled trial exploring the efficacy of paroxetine for the treatment of premenstrual dysphoria 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA)"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001396.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0924-977X(01)80424-7","article-title":"A placebo controlled study of the efficacy of intermittent and continuous treatment with paroxetine for premenstrual dysphoric disorder (PMDD)","volume":"11","author":"Landen","year":"2001","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0034|cit34","unstructured":"Landen MS A placebo-controlled study to investigate the onset of action of paroxetine in premenstrual dysphoria clinicaltrials.gov\/ct2\/show\/NCT00516113"},{"issue":"6489","key":"10.1002\/14651858.CD001396.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/bmj.305.6849.346","article-title":"Fluoxetine treatment of severe premenstrual syndrome","volume":"305","author":"Menkes","year":"1992","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00004850-199300820-00003","article-title":"Fluoxetine treatment of severe premenstrual syndrome","volume":"8","author":"Menkes","year":"1993","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0149-2918(02)85043-3","article-title":"Weekly luteal phase dosing with enteric coated fluoxetine 90mg in premenstrual dysphoric disorder: a randomised, double blind, placebo controlled clinical study","volume":"24","author":"Miner","year":"2002","journal-title":"Clinical Therapeutics"},{"issue":"Suppl","key":"10.1002\/14651858.CD001396.pub4-BIB0038|cit38","first-page":"87","article-title":"Predictors of response to luteal phase fluoxetine treatment of PMDD","volume":"5","author":"Miner","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0301-2115(97)02741-3","article-title":"Fluoxetine in the treatment of premenstrual syndrome","volume":"73","author":"Ozeren","year":"1997","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00004714-199708000-00004","article-title":"Comparison of fluoxetine, bupropion and placebo in the treatment of premenstrual dysphoric disorder","volume":"17","author":"Pearlstein","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0041|cit41","unstructured":"GlaxoSmithKline NZ Phone call from a representative of GlaxoSmithKline New Zealand (in response to an email sent by J Marjoribanks) confirming that 29060\/677 (Cohen 2004) and 29060\/689 (Pearlstein 2005) were separate studies"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0042|cit42","unstructured":"A double-blind, placebo-controlled, 3-arm, fixed-dose study of paroxetine CR continuous treatment (12.5 mg\/day and 25 mg\/day) for premenstrual dysphoric disorder https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=29060\/689"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0043|cit43","unstructured":"Email to Jane Marjoribanks from Teri Pearlstein advising that participants in Pearlstein 2005 and Cohen 2004 did not, to her knowledge, overlap."},{"key":"10.1002\/14651858.CD001396.pub4-BIB0044|cit44","unstructured":"Pearlstein T Bellew K Endicott J Steiner M Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double blind, placebo controlled trial 41st Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 2002 Dec 8-12; San Juan (Puerto Rico)"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4103\/abr.abr_49_20","article-title":"Saffron for the management of premenstrual dysphoric disorder: a randomized controlled trial","volume":"9","author":"Rajabi","year":"2020","journal-title":"Advanced Biomedical Research"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001396.pub4-BIB0046|cit46","first-page":"99","article-title":"Fluoxetine improves social functioning in women with premenstrual dysphoria","volume":"70","author":"Dillon","year":"2000","journal-title":"International Journal of Gynecology and Obstetrics"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0047|cit47","first-page":"178","article-title":"Efficacy of fluoxetine in improving mood symptoms and social impairments in patients with PMDD","volume":"42","author":"Koke","year":"2001","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0048|cit48","first-page":"96","article-title":"Fluoxetine's efficacy in improving mood. physical and social impairment symptoms associated with PMDD","volume":"Abstract Book 3","author":"Nilsson M Judge","year":"2000","journal-title":"International Journal of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0049|cit49","unstructured":"Steiner M Babcock S McCray SD Romano S Fluoxetine's efficacy in improving premenstrual dysphoric disorder 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington (DC)"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0050|cit50","unstructured":"Steiner M Babcock S Steinberg SI Stewart DE Carter D Berger C Fluoxetine's efficacy in improving physical symptoms associated with PDD: results from a multisite, randomized placebo controlled trial 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington (DC)"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00737-002-0162-2","article-title":"Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder","volume":"6","author":"Steiner","year":"2003","journal-title":"Archives of Women's Mental Health"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001396.pub4-BIB0052|cit52","first-page":"247","article-title":"Fluoxetine improves social functioning in women with premenstrual dysphoric disorder (PMDD)","volume":"3","author":"Steiner","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001396.pub4-BIB0053|cit53","first-page":"D147","article-title":"Fluoxetine's effect on food craving during the luteal phase in women with premenstrual dysphoric disorder (PMDD)","volume":"70","author":"Steiner","year":"2000","journal-title":"International Journal of Gynecology and Obstetrics"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/13651500510029002","article-title":"Assessment of sexual drive and desire in women with premenstrual dysphoric disorder who have been treated with fluoxetine","volume":"9","author":"Steiner","year":"2005","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD001396.pub4-BIB0055|cit55","first-page":"208","article-title":"Fluoxetine's efficacy in improving physical symptoms associated with PMDD","volume":"9","author":"Steiner","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0056|cit56","first-page":"208","article-title":"Fluoxetine's efficacy in improving physical symptoms associated with PMDD","volume":"Suppl","author":"Steiner","year":"2001","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0306-5456(00)00120-0","article-title":"The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder","volume":"108","author":"Steiner","year":"2001","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0058|cit58","first-page":"208","article-title":"Efficacy of fluoxetine in improving mood symptoms, physical symptoms and social impairment in patients with PMDD","volume":"Suppl","author":"Steiner","year":"2001","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM199506083322301","article-title":"Fluoxetine in the treatment of premenstrual dysphoric disorder","volume":"332","author":"Steiner","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0924-977X(00)80154-6","article-title":"Premenstrual dysphoric disorder (PMDD) and work efficiency: response to fluoxetine in a randomized clinical trial","volume":"10","author":"Steiner","year":"2000","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0061|cit61","first-page":"226","article-title":"Premenstrual dysphoric disorder (PMDD) and work efficiency: response to fluoxetine in a randomized clinical trial","volume":"Suppl","author":"Steiner","year":"2001","journal-title":"Journal of European College of Neuropsychopharmacology"},{"issue":"Suppl","key":"10.1002\/14651858.CD001396.pub4-BIB0062|cit62","first-page":"340S","article-title":"Premenstrual dysphoric disorder and work efficiency: response to fluoxetine in a randomized clinical trial","volume":"2","author":"Trzepacz","year":"2001","journal-title":"World Journal of Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0063|cit63","first-page":"184","article-title":"Premenstrual dysphoric disorder and work efficiency: response to fluoxetine in a randomized clinical trial","volume":"42","author":"Trzepacz","year":"2001","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0064|cit64","unstructured":"Gee M Bellew K Holland F van Erp E Perera P McCafferty J Luteal phase dosing of paroxetine controlled release is effective in treating PMDD 156th Annual Meeting American Psychiatric Association; 2003 May 17-22; San Francisco (CA)"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0065|cit65","unstructured":"A double-blind, placebo-controlled, 3-arm, fixed-dose study of paroxetine CR intermittent dosing (12.5 mg and 25 mg) for premenstrual dysphoric disorder www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F717&studyId=CA9A3538-05F2-43D8-A1E2-342281DDD178&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ajog.2005.01.021","article-title":"Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder","volume":"193","author":"Steiner","year":"2005","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0067|cit67","unstructured":"A randomized, double-blind, placebo-controlled trial of intermittent treatment with paroxetine 10mg\/day and 20mg\/day versus placebo in Canadian women with premenstrual dysphoric disorder www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F621&studyId=8696C1BE-93D7-4883-AD54-2BC6CF7740BB&compound=paroxetine"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0068|cit68","unstructured":"Hamilton Health Sciences Corporation Luteal phase administration of paroxetine for the treatment of PMDD: a randomized, double-blind, placebo-controlled trial in Canadian women clinicaltrials.gov\/ct2\/show\/NCT00620581"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4088\/JCP.v69n0616","article-title":"Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women","volume":"69","author":"Steiner","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0070|cit70","first-page":"290","article-title":"Fluoxetine in the treatment of late luteal phase dysphoric disorder","volume":"52","author":"Stone","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0071|cit71","first-page":"331","article-title":"Fluoxetine in the treatment of premenstrual syndrome","volume":"26","author":"Stone","year":"1990","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD001396.pub4-BIB0072|cit72","first-page":"41","article-title":"Sertraline in the treatment of premenstrual dysphoric disorder","volume":"32","author":"Yonkers","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0893-133X(96)00245-X","article-title":"Fluoxetine in the treatment of premenstrual dysphoria","volume":"16","author":"Su","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00004714-199810000-00007","article-title":"Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?","volume":"18","author":"Wikander","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0075|cit75","first-page":"339","article-title":"Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study","volume":"80","author":"Wood","year":"1992","journal-title":"Obstetrics and Gynecology"},{"issue":"12","key":"10.1002\/14651858.CD001396.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jama.1997.03550120043031","article-title":"Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment","volume":"278","author":"Yonkers","year":"1997","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/JCP.0b013e31829c7697","article-title":"A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome","volume":"33","author":"Yonkers","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001396.pub4-BIB0078|cit78","first-page":"S294","article-title":"T131. What symptoms trigger symptom-onset serotonin reuptake inhibitor treatment in premenstrual dysphoric disorder? A prospective evaluation","volume":"42","author":"Forray","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD001396.pub4-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1001\/jamapsychiatry.2015.1472","article-title":"Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial","volume":"72","author":"Yonkers","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4088\/JCP.v59n0206","article-title":"Treatment of PDD with sertraline during the luteal phase: a randomised, double-blind, placebo controlled crossover trial","volume":"59","author":"Young","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0081|cit81","unstructured":"Young SA Hurt PH Benedek DM Howard RS Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double blind placebo controlled crossover trial American Psychiatric Association 150th Annual Meeting; 1997 May 17-22; San Diego (CA)"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0082|cit82","first-page":"228","article-title":"Intermittent versus continuous sertraline therapy in the treatment of premenstrual dysphoric disorders","volume":"46","author":"Alpay","year":"2001","journal-title":"International Journal of Fertility"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00004850-199300840-00018","article-title":"Treatment of premenstrual syndrome with fluoxetine: an open study","volume":"8","author":"Brandenburg","year":"1993","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0084|cit84","first-page":"235","article-title":"Premenstrual dysphoric disorder: long term treatment with fluoxetine and discontinuation","volume":"25","author":"De la Gandara Martin","year":"1997","journal-title":"Actas Luso-Espanolas de Neurologia, Psiquiatria y Ciencias Afines"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0020-7292(98)00035-6","article-title":"A double blind trial of four medications to treat severe premenstrual syndrome","volume":"62","author":"Diegoli","year":"1998","journal-title":"International Journal of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00007611-199305000-00003","article-title":"Open trial of fluoxetine therapy for premenstrual syndrome","volume":"86","author":"Elks","year":"1993","journal-title":"Southern Medical Journal"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0087|cit87","first-page":"7","article-title":"Sertraline versus desipramine in the treatment of premenstrual syndrome: an open label trial","volume":"57","author":"Freeman","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0088|cit88","unstructured":"Freeman EW Rickels K Sondheimer SJ Comparison of serotonergic and noradrenergic antidepressant medications in treatment of premenstrual syndrome (PMS) XXIst Collegium Internationale Neuro-psychopharmacologicum; 1998 Jul 12-16; Glasgow (UK)"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0089|cit89","unstructured":"Freeman EW Rickels K Sondheimer SJ Sertraline versus desipramine in PMS treatment 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto (Canada)"},{"issue":"1","key":"10.1002\/14651858.CD001396.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004714-199902000-00002","article-title":"Full or half cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant","volume":"19","author":"Freeman","year":"1999","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD001396.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4088\/JCP.v61n0807","article-title":"Predictors of response to sertraline treatment of severe premenstrual syndromes","volume":"61","author":"Freeman","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/15246090260137635","article-title":"Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study","volume":"11","author":"Freeman","year":"2002","journal-title":"Journal of Womens Health & Gender-based Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001396.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"769","DOI":"10.4088\/JCP.v66n0616","article-title":"A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder","volume":"66","author":"Freeman","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0094|cit94","unstructured":"A 3-month, double-blind, placebo-controlled, fixed-dose, extension study of paroxetine CR (12.5 mg and 25 mg\/day) continuous treatment for PMDD patients completing studies 29060\/677, 688 or 689 www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=29060%2F711&studyId=4A384A1A-46F7-4E8B-915B-4B324BB64491&compound=paroxetine"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub4-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3109\/01674820209074672","article-title":"A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder","volume":"23","author":"Hunter","year":"2002","journal-title":"Journal of Psychosomatic Obstetrics & Gynecology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0096|cit96","unstructured":"Compare the effect of acupressure therapy and fluoxetine on the symptoms of premenstrual syndrome: a randomized clinical trial irct.behdasht.gov.ir\/trial\/39241"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/npp.2008.86","article-title":"Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability","volume":"34","author":"Landen","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0098|cit98","volume-title":"Ensaio Cl\u00ednico com Fluoxetina em Baixa Dose para o Tratamento da S\u00edndrome Pr\u00e9-menstrual: um Estudo Piloto [Clinical Trial with Low Dose of Fluoxetine for the Treatment of Premenstrual Syndrome: a Pilot Study] [Masters thesis]","author":"Maranho","year":"2020"},{"issue":"6","key":"10.1002\/14651858.CD001396.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1089\/jwh.2007.0491","article-title":"Variable dosing of sertraline for premenstrual exacerbation of depression: a pilot study","volume":"17","author":"Miller","year":"2008","journal-title":"Journal of Women's Health"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub4-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00404-012-2594-x","article-title":"Premenstrual syndrome: a single-blind study of treatment with buspirone versus fluoxetine","volume":"287","author":"Nazari","year":"2013","journal-title":"Archives of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0101|cit101","unstructured":"Yonkers KA Antidepressant treatment for premenstrual syndrome and premenstrual dysphoric disorder clinicaltrials.gov\/ct2\/show\/NCT00048854"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0102|cit102","first-page":"1760","article-title":"Comparison of saffron versus fluoxetine in treatment of women with premenstrual syndrome: a randomized clinical trial study","volume":"14","author":"Nemat-Shahi","year":"2020","journal-title":"Indian Journal of Forensic Medicine and Toxicology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0103|cit103","first-page":"332","article-title":"Long term fluoxetine treatment of late luteal phase dysphoric disorder","volume":"55","author":"Pearlstein","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0104|cit104","unstructured":"Pearlstein T Haskett R Stout A Frank E Endicott J Sertraline improves psychosocial functioning in premenstrual dysphoric disorder 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto (Canada)"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4088\/JCP.v61n0205","article-title":"Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo","volume":"61","author":"Pearlstein","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"issue":"003","key":"10.1002\/14651858.CD001396.pub4-BIB0106|cit106","first-page":"37","article-title":"Comparison between continuous and intermittent treatment with citalopram for premenstrual dysphoric disorder","volume":"26","author":"Ramos","year":"2003","journal-title":"Salud Mental"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0107|cit107","first-page":"161","article-title":"Fluoxetine in the treatment of PMS","volume":"48","author":"Rickels","year":"1990","journal-title":"Current Therapeutic Research"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s43032-019-00080-x","article-title":"Does adding fluoxetine to combined oral contraceptives containing drospirenone improve the management of severe premenstrual syndrome? A 6-month randomized double-blind placebo-controlled three-arm trial","volume":"27","author":"Shehata","year":"2020","journal-title":"Reproductive sciences (Thousand Oaks, Calif.)"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0109|cit109","first-page":"771","article-title":"Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria","volume":"33","author":"Steiner","year":"1997","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0447.1992.tb01440.x","article-title":"Clomipramine effectively reduces irritability and dysphoria: a placebo controlled trial","volume":"85","author":"Sundblad","year":"1992","journal-title":"Acta Psychiatrica Scandinavia"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/npp.1993.52","article-title":"Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo controlled trial","volume":"9","author":"Sundblad","year":"1993","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0924-977X(97)00404-5","article-title":"A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment","volume":"7","author":"Sundblad","year":"1997","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF02244113","article-title":"Fluvoxamine in the treatment of menstrually related disorders","volume":"102","author":"Veeninga","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1440-1819.2007.01785.x","article-title":"Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols","volume":"62","year":"2008","journal-title":"Psychiatry and Clinical Neurosciences"},{"issue":"1","key":"10.1002\/14651858.CD001396.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004714-199602000-00002","article-title":"Paroxetine as a treatment for premenstrual dysphoric disorder","volume":"16","author":"Yonkers","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/01.jcp.0000203197.03829.ae","article-title":"Symptom-onset treatment for women with premenstrual dysphoric disorder","volume":"26","author":"Yonkers","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0117|cit117","unstructured":"Dienogest versus luteal phase fluoxetine in the management of premenstrual syndrome clinicaltrials.gov\/ct2\/show\/NCT02427334"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0118|cit118","unstructured":"Does adding oral contraceptives to fluoxetine improve the management of premenstrual syndrome? clinicaltrials.gov\/ct2\/show\/NCT02562053"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0119|cit119","unstructured":"American College of Obstetricians and Gynecologists Premenstrual syndrome ACOG Practice Bulletin No. 15. Washington, DC: ACOG 2000"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders. DSM-5","author":"American Psychiatric Association","year":"2013"},{"issue":"8","key":"10.1002\/14651858.CD001396.pub4-BIB0121|cit121","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005290.pub2","article-title":"Acupuncture and acupressure for premenstrual syndrome","author":"Armour","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.maturitas.2012.03.007","article-title":"Premenstrual syndrome (PMS): a peri-menopausal perspective","volume":"72","author":"Baker","year":"2012","journal-title":"Maturitas"},{"issue":"8","key":"10.1002\/14651858.CD001396.pub4-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1136\/bjsports-2020-102792","article-title":"Prevalence and frequency of menstrual cycle symptoms are associated with availability to train and compete: a study of 6812 exercising women recruited using the Strava exercise app","volume":"55","author":"Bruinvels","year":"2021","journal-title":"British Journal of Sports Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1176\/appi.ajp.2012.11081302","article-title":"Premenstrual dysphoric disorder: evidence for a new category for DSM-5","volume":"169","author":"Epperson","year":"2012","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub4-BIB0125|cit125","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003415.pub4","article-title":"Progesterone for premenstrual syndrome","author":"Ford","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/archgenpsychiatry.2008.547","article-title":"Time to relapse after short-term or long-term sertraline treatment for severe premenstrual syndromes","volume":"66","author":"Freeman","year":"2009","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001396.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/AOG.0b013e318236edf2","article-title":"Clinical subtypes of premenstrual syndrome and responses to sertraline treatment","volume":"118","author":"Freeman","year":"2011","journal-title":"Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/jnr.24632","article-title":"Pharmacological sex hormone manipulation as a risk model for depression","volume":"98","author":"Frokjaer","journal-title":"Journal of Neuroscience Research"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0129|cit129","unstructured":"Public Disclosure of Clinical Research www.gsk.com\/media\/10585\/gsk-position-on-disclosure-of-clinical-research-sept-2023.pdf"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0130|cit130","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2022"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0131|cit131","first-page":"e73","article-title":"Management of premenstrual syndrome","volume":"124","author":"Green","year":"2017","journal-title":"BJOG"},{"issue":"7","key":"10.1002\/14651858.CD001396.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"566,569","DOI":"10.1017\/S1092852900016849","article-title":"Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough","volume":"13","author":"Halbreich","year":"2008","journal-title":"CNS Spectrum"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0133|cit133","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0134|cit134","unstructured":"Higgins JP Thomas J Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022) Available from training.cochrane.org\/handbook\/archive\/v6.3 2022"},{"issue":"8","key":"10.1002\/14651858.CD001396.pub4-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2165\/00023210-200620080-00005","article-title":"Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome","volume":"20","author":"Himei","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0136|cit136","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9781139696913","volume-title":"Psychological Disorders in Obstetrics and Gynaecology for the MRCOG and Beyond","author":"Ismail","year":"2006"},{"issue":"1","key":"10.1002\/14651858.CD001396.pub4-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006414.pub2","article-title":"Chinese herbal medicine for premenstrual syndrome","author":"Jing","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD001396.pub4-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"409","DOI":"10.31887\/DCNS.2008.10.4\/kkelly","article-title":"Toward achieving optimal response: understanding and managing antidepressant side effects","volume":"10","author":"Kelly","year":"2008","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10880-012-9299-y","article-title":"Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis","volume":"19","author":"Kleinstauber","year":"2012","journal-title":"Journal of Clinical Psychology in Medical Settings"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0140|cit140","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated October 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"issue":"6, Art. No.: CD","key":"10.1002\/14651858.CD001396.pub4-BIB0141|cit141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006586.pub5","article-title":"Oral contraceptives containing drospirenone for premenstrual syndrome","author":"Ma","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD001396.pub4-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1177\/0269881108093582","article-title":"Review: problems associated with long-term treatment with selective serotonin reuptake inhibitors","volume":"23","author":"Moret","year":"2009","journal-title":"Journal of Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD001396.pub4-BIB0143|cit143","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011330","article-title":"Gonadotropin-releasing hormone (GnRH) analogues for premenstrual syndrome (PMS)","author":"Naheed","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub4-BIB0144|cit144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010503.pub2","article-title":"Oestrogen for premenstrual syndrome","author":"Naheed","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00737-010-0201-3","article-title":"Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus","volume":"14","author":"O'Brien","year":"2011","journal-title":"Archives of Womens Mental Health"},{"issue":"13","key":"10.1002\/14651858.CD001396.pub4-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2165\/00003495-200262130-00004","article-title":"Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder","volume":"62","author":"Pearlstein","year":"2002","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0147|cit147","first-page":"37","volume-title":"The Premenstrual Syndromes: PMS and PMDD","author":"Pearlstein","year":"2007"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0002-9378(93)90079-X","article-title":"Diagnostic and treatment results from a south-eastern academic center-based premenstrual syndrome clinic: the first year","volume":"169","author":"Plouffe","year":"1993","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14656566.9.3.429","article-title":"The pharmacologic management of premenstrual dysphoric disorder","volume":"9","author":"Rapkin","year":"2008","journal-title":"Expert Opinion in Pharmacotherapy"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0150|cit150","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0151|cit151","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated August 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6 10.1002\/9781119536604.ch14","DOI":"10.1002\/9781119536604.ch14"},{"issue":"5","key":"10.1002\/14651858.CD001396.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/AOG.0b013e31816fd73b","article-title":"Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. A meta-analysis","volume":"111","author":"Shah","year":"2008","journal-title":"Obstetrics and Gynecology"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub4-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy","volume":"358","author":"Turner","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0154|cit154","volume-title":"International Classification of Diseases, ICD-11","author":"World Health Organization","year":"2022"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ajog.2017.05.045","article-title":"Premenstrual disorders","volume":"218","author":"Yonkers","year":"2018","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/NMD.0000000000000128","article-title":"A diagnostic and statistical manual of mental disorders history of premenstrual dysphoric disorder","volume":"202","author":"Zachar","year":"2014","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"3","key":"10.1002\/14651858.CD001396.pub4-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001396","article-title":"Selective serotonin reuptake inhibitors for premenstrual syndrome","author":"Brown","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001396.pub4-BIB0158|cit158","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001396.pub2","article-title":"Selective serotonin reuptake inhibitors for premenstrual syndrome","author":"Brown","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001396.pub4-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0140-6736(00)02754-9","article-title":"Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review","volume":"356","author":"Dimmock","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD001396.pub4-BIB0160|cit160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001396.pub3","article-title":"Selective serotonin reuptake inhibitors for premenstrual syndrome","author":"Marjoribanks","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:19:13Z","timestamp":1765297153000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001396.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecology and Fertility Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":160,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001396.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]}}}